CervoMed (CRVO) Projected to Post Earnings on Monday

Posted by on May 4th, 2026

CervoMed (NASDAQ:CRVO – Get Free Report) is projected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.7875) per share and revenue of $0.0710 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

CervoMed (NASDAQ:CRVO – Get Free Report) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). CervoMed had a negative return on equity of 96.04% and a negative net margin of 672.80%.The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.84 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Price Performance

Shares of NASDAQ CRVO traded up $0.19 during mid-day trading on Monday, hitting $3.90. 15,495 shares of the stock traded hands, compared to its average volume of 72,523. CervoMed has a twelve month low of $3.51 and a twelve month high of $13.13. The company has a market cap of $36.08 million, a PE ratio of -1.31 and a beta of -0.63. The firm has a 50 day simple moving average of $4.08 and a two-hundred day simple moving average of $6.15.

Analyst Upgrades and Downgrades

CRVO has been the subject of several research analyst reports. Chardan Capital lifted their price objective on CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of CervoMed in a report on Monday, April 20th. D. Boral Capital restated a “buy” rating and issued a $31.00 target price on shares of CervoMed in a research note on Wednesday, April 22nd. Roth Mkm cut their target price on CervoMed from $19.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Finally, upgraded CervoMed to a “strong-buy” rating in a research note on Tuesday, February 3rd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

View Our Latest Research Report on CervoMed

Institutional Investors Weigh In On CervoMed

Institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its position in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after buying an additional 1,526 shares in the last quarter. Marshall Wace LLP bought a new position in CervoMed in the second quarter valued at $76,000. XTX Topco Ltd bought a new position in CervoMed in the fourth quarter valued at $81,000. Jane Street Group LLC bought a new position in CervoMed in the fourth quarter valued at $88,000. Finally, Dimensional Fund Advisors LP bought a new position in CervoMed in the fourth quarter valued at $110,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

(Get Free Report)

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.

Read More

Earnings History for CervoMed (NASDAQ:CRVO)

Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.